Update on clinical trials for myeloproliferative neoplasms

Claire Harrison, MD, DM, FRCP, FRCPath, from the Guy's and St. Thomas' NHS Foundation Trust, London, UK, gives an overview of clinical trials in myeloproliferative neoplasms (MPN) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She discusses essential thrombocythemia (ET), where data from the MPD-RC 112 study (NCT01259856), PT-1 trial (NCT00175838) as well as the MAJIC study (ISRCTN61925716) will be available soon. In the field of polycythemia vera (PV), more data are also expected soon from the RESPONSE-2 (NCT02038036) and PROUD-PV (NCT01949805) studies, as well as from MPD-RC 112. Dr Harrison also speaks about trials in the myelofibrosis field. Results were recently seen in the PERSIST-2 trial (NCT02055781), and data from SIMPLIFY-1 (NCT01969838) and SIMPLIFY-2 (NCT02101268) are expected soon. She also mentions the JAK ALLO study (NCT01795677) and new agents for anemia management.